EMDAR Injection

ONDANSETRON 4mg

PHARMACOLOGY

1. Pharmacokinetics: -

• Absorption: Owing to hepatic first-pass metabolism, its bioavailability is only about 60%.
• Distribution: Plasma protein binding of ondensetron as measured in vitro was 70% to 76%, over the Pharmacologic concentration range of 10 to 500 ng/mL. Circulating drug also distributes into erythrocytes.
• Metabolism: Ondensetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine. The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation.
• Elimination: In adult cancer patients, the mean ondensetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.

INDICATION

Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin 50 mg/ Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively,